RANBAXY JV LAUNCHES ANTI-DIABETES DRUG IN JAPAN

Nihon Pharmaceuticals Industry (NPI), a joint venture between Ranbaxy Laboratories and Nippon Chemiphar (NC), has launched its first, co-developed product Vogseal 0.2mg & 0.3mg tablets (generic Voglibose) in Japan. According to a release issued by Ranbaxy to the BSE today, the product is used for the treatment of diabetes, and will be made available at medical institutions across the country through a network of wholesalers.

Big News Network (http://feeds.bignewsnetwork.com/redir.php?jid=e1ee9b09d426420a&cat=6dcd932030878143)